In 2022, the FDA approved T-DXd for cases of previously treated metastatic NSCLC carrying a HER2-activating mutation based on the DESTINY-LUNG02 phase II trial, which tested the drug on patients with single nucleotide variants or exon 20 insertions [130]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.